Fiche publication
Date publication
octobre 2025
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry
,
Dr BENDER Laura
Tous les auteurs :
Bischoff H, Somme L, Petit T
Lien Pubmed
Résumé
Neoadjuvant therapy has become the standard of care in early-stage triple-negative breast cancer (TNBC), providing both prognostic information and a platform for treatment individualization. The achievement of a pathological complete response (pCR) is strongly associated with excellent long-term outcomes, whereas the presence of residual disease (RD) indicates a markedly increased risk of recurrence. This dual prognostic value has established post-neoadjuvant treatment as a critical arena for risk-adapted strategies. In patients achieving pCR, de-escalation of adjuvant therapy is under active investigation, with several randomized trials assessing whether surveillance may safely replace prolonged immunotherapy. Conversely, the management of patients with RD has become increasingly complex, as clinicians must navigate between established options such as capecitabine, olaparib, and pembrolizumab, while antibody-drug conjugates are likely to emerge as future therapeutic options in this high-risk setting. In parallel, locoregional approaches are evolving, with trials evaluating axillary de-escalation and even the omission of surgery in highly selected cases. Looking forward, the integration of biomarkers such as circulating tumor DNA and tumor-infiltrating lymphocytes may help refine these strategies, paving the way toward truly personalized post-neoadjuvant care in TNBC.
Mots clés
antibody–drug conjugates, capecitabine, de-escalation, immunotherapy, neoadjuvant therapy, olaparib, pathological complete response, residual disease, triple-negative breast cancer
Référence
Cancers (Basel). 2025 10 10;17(20):
